Daewoong Pharmaceutical Receives Approval to Change Clinical Trial Plan for COVID-19 Treatment
[Asia Economy Reporter Lee Junhyung] Daewoong Pharmaceutical announced on the 17th that it has received approval from the Ministry of Food and Drug Safety to change the clinical trial plan for the Phase 2/3 clinical trial of the novel coronavirus disease (COVID-19) treatment DWJ1248.
In this Phase 2/3 clinical trial, the efficacy and safety of DWJ1248 will be evaluated in patients with mild to moderate COVID-19.
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- Debris from Attack on Namu Arrives in Korea: "Detailed Analysis by Specialized Agencies Planned"
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
The company stated, "The probability that the clinical trial drug will receive final approval as a pharmaceutical product is about 10%," and added, "There is also a possibility that the commercialization plan may be changed or abandoned if the results during the clinical trial and product approval process do not meet expectations."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
